Share

Phase III Trials Set After Potential Type 1 Diabetes Vaccine Shows Promise

[Editor’s note: This post has been updated to clarify that the meta-analysis published in Diabetologia and the Phase IIb trial were separate studies.] Earlier this fall, Phase IIb topline results of the DIAGNODE-2 trial demonstrated a potential type 1 diabetes vaccine GAD-alum —  an immunomodulating antigen-specific therapy – had a highly significant and clinically relevant...
Share

Eureka 2020! Part I – Top Endocrine Science According to Endocrinology Editors

Endocrinology cover jan 21 For the sixth year running, Endocrine News talks to editors from Endocrine Society publications to get the scoop on the top endocrine discoveries of 2020. In this first installment, we talk to Endocrinology editors about what they think this year’s most significant studies were that will impact endocrine science for years to come. Despite the...
Share

Insulin Titration Software Combined with CGM Enables Patients with Diabetes to Improve Time in Range

First study to utilize CGM data with FDA-cleared, cloud-based titration software suggests significantly improved outcomes for patients while optimizing clinical resources This past summer, Glytec published the first proof-of-concept study that combines FDA-cleared remote insulin titration software and data from continuous glucose monitoring (CGM) systems. Results of the study, presented at the American Diabetes Association’s...
Share

Positive Topline Results Announced in Type 1 Diabetes Clinical Trial

A clinical trial investigating a possible novel treatment of early-onset type 1 diabetes last month met the primary endpoint assessing the safety and tolerability of a new class of microbe-based therapeutic agents. Precigen ActoBio is evaluating this therapy — AG019 ActoBiotics — as a monotherapy and in combination with teplizumab. AG019 is formulated as an...
Share

Insulin Sensitivity Improves with Testosterone Therapy in Men with Type 2 Diabetes and Hypogonadism

About a third of men with type 2 diabetes (T2D) also have hypogonadotropic hypogonadism (HH). This comorbidity makes that subgroup more insulin resistant, with increased adiposity and less lean mass, according to research published recently in The Journal of Clinical Endocrinology & Metabolism. A team led by Paresh Dandona, BSc, MB, BS, DPhil, FRCP, of...

Diabetes Research Articles

Get the most up to date news on diabetes research and treatment. For more information read the latest issue of Endocrine News.